CTO-17-101

Please Note: This trial is no longer enrolling new participants

Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer

PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer
Mayer EL;Ren Y;Wagle N;Mahtani R;Ma C;DeMichele A;Cristofanilli M;Meisel J;Miller KD;Abdou Y;Riley EC;Qamar R;Sharma P;Reid S;Sinclair N;Faggen M;Block CC;Ko N;Partridge AH;Chen WY;DeMeo M;Attaya V;Okpoebo A;Alberti J;Liu Y;Gauthier E;Burstein HJ;Regan MM;Tolaney SM;